Pharma Legal Handbook Need to know about regulation, pricing and reimbursement in Colombian pharma? Read on! Prepared in association with Cavelier Abogados, a leading global law firm, this is an extract from The Pharma Legal Handbook: Colombia, available to purchase here for GBP 119. 1. What are the regulatory authorities with jurisdiction over…
Americas While regulatory agencies in several Latin American countries have made significant efforts to improve processes and accelerate approval times, a number of access hurdles still remain across the region. Here, the representatives of some of pharma’s most important companies in LatAm share their experiences of the evolution of market access…
Brazil Rolf Hoenger describes how Roche is driving access and awareness for innovative medicines in Latin America and weighs in on a number of important topics, from regulatory harmonisation in the region to digitalisation, clinical trials, Roche’s ongoing global transformation, and how inter-industry collaboration can foster true progress in healthcare. …
Brazil After a successful international career, Andre Vivan da Silva recently returned to his native Brazil to become GSK’s country manager. He explains the importance of vaccination, in Brazil, and HIV in a country where GSK’s products treat at least half of its HIV patients. He also speaks about the company’s…
Americas Latin America (LatAm) Area Lead for Astellas Sandra Ramirez outlines the Japanese company’s presence in the region, its efforts to partner with local stakeholders to improve patient access, and the consolidation of its operations in the priority market of Mexico. LatAm as a region offers many opportunities for innovation.…
Americas Two Big Pharma SVPs with responsibility for the entirety of Latin America weigh in on the management challenges inherent in LatAm and what they look for when appointing country managers in their region. LatAm’s regional pharma market of USD 98 billion looks set to be the fastest growing in…
LatAm Novo Nordisk’s Latin America lead Allan Finkel outlines the “alarming” burden of diabetes and obesity in his region, the progress that has been made via national campaigns against diabetes, and why countries in LatAm need to recognise obesity as the disease it is considering its heavy impact on patients’ lives…
LatAm A roundup of some of the latest from Latin American pharma, including India’s interest in the South American market, Bayer’s USD 361 million investment in Mexico, the EU’s partnership to boost investment in vaccines and drug production in the region, Panama’s cannabis strategy, and Brazil’s manufacturing attractiveness. Indian pharma…
LatAm GSK’s head of Emerging Markets, Luis Arosemena, comments on the strategic importance of this wide-ranging country grouping for the company, the structure of his organisation in Latin America, the importance of the country manager role, and explains how strong institutions make up for volatility in Latin America. Five of…
Brazil The latest from Brazilian Pharma, including the approval of home grown cannabis for medical use, Cellera Farma’s partnership with Ferring, a considerable increase in demand for oncology drugs, and a dire diabetes prediction. Brazil court approves home grown cannabis for medical use (ABC News) A top court in Brazil…
Americas Collaboration, convergence, and other best practices have been at the center of discussions related to the regulatory environment in Latin America and the Caribbean, including DIA’s Latin America Regulatory Conference (LARC) 2022, where voices from global regulators, regional and international organizations, industry, and academia discussed the strategies supporting current practices and…
LatAm Writing in the March edition of DIA’s Global Forum magazine, the University of Southern California’s Viktoria Magyar looks at how Latin American regulatory bodies adapted to the COVID-19 pandemic and what some of its longer-term impacts on regulatory activities in the region might be. Driven by increasing workloads, limited…
See our Cookie Privacy Policy Here